Picture loading failed.

Anti-RSV gpF therapeutic antibody (Pre-made Suptavumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Suptavumab (INN; development code (REGN2222) is a humanized monoclonal antibody designed for the prevention of medically attended lower respiratory tract disease due to respiratory syncytial virus.

Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-535-1mg 1mg 3090
GMP-Bios-ab-535-10mg 10mg 21890
GMP-Bios-ab-535-100mg 100mg 148000
GMP-Bios-ab-535-xmg >100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-RSV gpF therapeutic antibody (Pre-made Suptavumab biosimilar,Whole mAb)
INN Name Suptavumab
TargetRSV gpF
FormatWhole mAb
DerivationHuman
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-III
Est. StatusDiscontinued
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2016
Year Recommended2017
CompaniesRegeneron Pharmaceuticals
Conditions Approvedna
Conditions Activena
Conditions DiscontinuedRespiratory syncytial virus infections
Development TechVelocImmune Mouse;VelociGene